A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Clinical trial NCT06760819 · RECRUITING
Trial details
- NCT number
- NCT06760819
- Sponsor
- Bayer
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-02-13
- Primary completion
- 2027-02-03
- Enrollment
- 111
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.